ABIVAX Société Anonyme (NASDAQ:ABVX) Short Interest Up 19.0% in December

ABIVAX Société Anonyme (NASDAQ:ABVX) was the target of a significant increase in short interest in the month of December. As of December 15th, there was short interest totalling 577,200 shares, an increase of 19.0% from the November 30th total of 484,900 shares. Currently, 1.1% of the shares of the company are sold short. Based on an average trading volume of 139,700 shares, the short-interest ratio is currently 4.1 days.

Analysts Set New Price Targets

ABVX has been the topic of a number of analyst reports. Citizens Jmp raised shares of ABIVAX Société Anonyme to a “strong-buy” rating in a report on Wednesday, December 4th. JMP Securities assumed coverage on ABIVAX Société Anonyme in a report on Wednesday, December 4th. They set an “outperform” rating and a $33.00 price objective for the company. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $38.67.

Institutional Investors Weigh In On ABIVAX Société Anonyme

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets lifted its holdings in ABIVAX Société Anonyme by 82.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company’s stock worth $150,000 after buying an additional 5,900 shares during the period. Walleye Capital LLC lifted its position in shares of ABIVAX Société Anonyme by 45.8% in the 3rd quarter. Walleye Capital LLC now owns 257,417 shares of the company’s stock worth $2,965,000 after purchasing an additional 80,807 shares during the period. abrdn plc boosted its stake in shares of ABIVAX Société Anonyme by 167.7% during the 3rd quarter. abrdn plc now owns 316,431 shares of the company’s stock valued at $3,645,000 after purchasing an additional 198,225 shares in the last quarter. Finally, Point72 Asset Management L.P. increased its position in shares of ABIVAX Société Anonyme by 28.2% during the third quarter. Point72 Asset Management L.P. now owns 542,900 shares of the company’s stock valued at $6,254,000 after buying an additional 119,300 shares during the period. 47.91% of the stock is currently owned by institutional investors.

ABIVAX Société Anonyme Trading Up 0.4 %

Shares of ABVX stock traded up $0.03 during trading hours on Monday, hitting $7.15. 129,186 shares of the company’s stock were exchanged, compared to its average volume of 99,057. ABIVAX Société Anonyme has a 12-month low of $6.65 and a 12-month high of $17.02. The business’s 50 day simple moving average is $9.06 and its 200-day simple moving average is $10.90.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.